Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus NEPHROFLOW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus NEPHROFLOW.
AMMONIA N 13 vs NEPHROFLOW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical